Contact
searchSearch
HMP Global
Login

Multiple Myeloma (ASH KOL Insights)

Insights on Multiple Myeloma
From the ASH Annual Meeting & Exposition

Dory Abelman, PhD, HBHSc
Conference Coverage
Ultra-Deep Whole Genome Sequencing of Cell-Free DNA Enhances MRD Detection and Risk Stratification in Multiple Myeloma
02/11/2026
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc, presents a blood-based cell-free DNA approach that accurately detects minimal residual disease and predicts relapse in multiple myeloma up to 1 year earlier than clinical progression.
Dory Abelman, PhD, HBHSc,...
02/11/2026
Oncology
Luciano Costa, MD
Videos
Teclistamab Plus Daratumumab Demonstrates Significant Survival Benefit for R/R Multiple Myeloma: MajesTEC-3 Trial
01/30/2026
Luciano J. Costa
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported results from the MajesTEC-3 trial which found teclistamab plus daratumumab delivered significant progression-free and overall survival benefits as early as a second line-therapy in multiple myeloma.
Luciano Costa, MD, reported...
01/30/2026
Oncology
Bilal Abid MD, MS, FACP, MRCP, FRCP
Conference Coverage
Evaluating Infection Patterns Among Patients With Multiple Myeloma Receiving BCMA-Targeting CAR T-Cell Therapy
01/26/2026
Bilal Abid, MD, MS, FACP, MRCP, FRCP
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP, FRCP, shared results from a large real-world analysis of infection patterns and outcomes among patients with R/R MM treated with BCMA CAR T–cell therapy.
Bilal Abid MD, MS, FACP, MRCP,...
01/26/2026
Oncology
Ira Zackon, MD
Conference Coverage
Real-World Analysis Shows Rapid Uptake of Bispecific Antibodies in Community Settings for Multiple Myeloma Treatment
01/22/2026
Ira Zackon, MD
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results which found bispecific antibody use is rapidly increasing in US community oncology practices for heavily pretreated multiple myeloma, with overall survival outcomes comparable to clinical trials.
Ira Zackon, MD, shared results...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Conference Coverage
KTX1001 Monotherapy Shows Clinical Activity and Manageable Safety for R/R Myeloma
01/22/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP, FASCO, shared that the oral NSD2 inhibitor, KTX1001, showed promising clinical activity with manageable safety for relapsed/refractory multiple myeloma, including high-risk t(4;14) disease.
Saad Usmani, MD, MBA, FACP,...
01/22/2026
Oncology
Ola Landgren, MD, PhD
Conference Coverage
Daratumumab Plus Teclistamab Demonstrates Favorable Safety and Efficacy for Smoldering Multiple Myeloma: REVIVE Study
01/22/2026
C. Ola Landgren, MD, PhD
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared early results from the phase 2 REVIVE study which showed daratumumab plus teclistamab can be safely administered for high-risk smoldering myeloma.
Ola Landgren, MD, PhD, shared...
01/22/2026
Oncology
Saad Usmani, MD, MBA, FACP, FASCO
Videos
Teclistamab Plus Talquetamab Shows Deep and Durable Responses for Extramedullary Multiple Myeloma: RedirecTT-1
01/08/2026
Saad Usmani, MD, MBA, FACP, FASCO
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP, FASCO, presented updated results from the phase 2 RedirecTT-1 trial which evaluated teclistamab plus talquetamab for relapsed/refractory multiple myeloma with extramedullary disease.
Saad Usmani, MD, MBA, FACP,...
01/08/2026
Oncology
Ran Reshef, MD, MSc
Conference Coverage
Relationship of Cilta-Cel Dose to PFS Outcomes for Patients With R/R Multiple Myeloma: Real-World Analysis
12/08/2025
Ran Reshef, MD, MSc
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of ciltacabtagene autoleucel were associated with improved progression-free survival without added toxicity, according to results from a real-world analysis presented by Ran Reshef, MD, MSc, at the 2025 ASH Annual Meeting &...
Higher cell doses of...
12/08/2025
Oncology
Adam Cohen, MD
Conference Coverage
Cevostamab Consolidation After BCMA CAR T-Cell Therapy for Patients With R/R Multiple Myeloma: "STEM" Trial
12/08/2025
Adam Cohen, MD
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting, Adam Cohen, MD, shares data from the “STEM” (Sequential T Cell-Engagement for Myeloma) phase 2 trial on cevostamab consolidation following BCMA CAR T-cell therapy for R/R MM.
At the ASH 2025 Annual Meeting,...
12/08/2025
Oncology
Mitul Gandhi, MD
Conference Coverage
Daratumumab Added to Lenalidomide Maintenance Therapy Following Transplant Improves Depth and Durability of MRD Response for MM: AURIGA Study
12/07/2025
Mitul Gandhi, MD
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide maintenance therapy following ASCT improved MRD-negative conversion and durability among newly diagnosed multiple myeloma patients, according to data presented at 2025 ASH Annual Meeting & Exposition.
Daratumumab plus lenalidomide...
12/07/2025
Oncology

Recent News

News
Low-Dose CT Screening Reduces Lung Cancer Mortality in a Non–Risk-Based Population
03/26/2026
Emily Estrada
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective analysis of patients enrolled in the Lung-Care project, low-dose CT screening significantly reduces lung cancer mortality in a non–risk-based population.
According to a prospective...
03/26/2026
Oncology
News
TTFields Plus Atezolizumab and Chemotherapy Improves Disease Control in Metastatic Pancreatic Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2 PANOVA-4 trial demonstrated that first-line treatment with TTFields plus atezolizumab and chemotherapy achieved a higher disease control rate compared with historical control among patients with metastatic pancreatic...
Results from the phase 2...
03/26/2026
Oncology
News
Ceralasertib Plus Durvalumab Does Not Improve Outcomes in Advanced Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3 LATIFY trial demonstrated that ceralasertib plus durvalumab did not improve survival outcomes compared with docetaxel in advanced non-small cell lung cancer.
Final results from the phase 3...
03/26/2026
Oncology
News
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3 OptiTROP-Lung03 trial demonstrate that sacituzumab tirumotecan significantly improves survival outcomes compared with docetaxel in previously treated patients with EGFR-mutated non-small cell lung cancer.
Updated results from the phase 3...
03/26/2026
Oncology
News
Osimertinib Plus Local Consolidative Therapy Improves PFS in EGFR-Mutated Non-Small Cell Lung Cancer
03/26/2026
Stephanie Holland
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2 NorthStar trial demonstrate that adding local consolidative therapy to osimertinib significantly improves outcomes in EGFR-mutated non-small cell lung cancer.
Results from the phase 2...
03/26/2026
Oncology
News
Belantamab Mafodotin Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma
03/25/2026
Stephanie Holland
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the DREAMM-6 trial demonstrated that belantamab mafodotin plus bortezomib and dexamethasone shows strong clinical promise with manageable safety in relapsed/refractory multiple myeloma.
Results from arm B of the...
03/25/2026
Oncology
FDA Approval
FDA Grants Approval to Relacorilant Plus Nab-Paclitaxel for Platinum-Resistant Ovarian Cancer, Fallopian Tube, or Primary Peritoneal Cancer
03/25/2026
Emily Estrada
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in combination with nab-paclitaxel for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic therapies, including bevacizumab.
The FDA approved relacorilant in...
03/25/2026
Oncology
News
Imlunestrant Demonstrates Favorable Safety Alone and With Abemaciclib in Advanced Breast Cancer
03/24/2026
Emily Estrada
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from the phase 3 EMBER-3 trial further support imlunestrant alone or in combination with abemaciclib in patients with ER-positive, HER2-negative advanced breast cancer.
Detailed safety findings from...
03/24/2026
Oncology
News
Early Dose Reductions Improve Persistence With Adjuvant Abemaciclib in High-Risk Early Breast Cancer
03/24/2026
Emily Estrada
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US Flatiron Health Research Database demonstrate that most patients with HR-positive, HER2-negative early breast cancer remain on adjuvant abemaciclib at 6 months, with dosing strategies playing a critical role in...
Real-world data from the US...
03/24/2026
Oncology
News
Clinical and Molecular Factors Influence Outcomes of Sevabertinib in HER2-Mutated NSCLC
03/24/2026
Stephanie Holland
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory analysis of the phase 1/2 SOHO-01 study suggest that clinical and molecular characteristics may influence treatment outcomes among patients with HER2-mutated non-small cell lung cancer receiving sevabertinib.
Results from an exploratory...
03/24/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use